On February 1, 2022, BISSELL Inc. and BISSELL Homecare, Inc., both of Grand Rapids, Michigan (collectively, "BISSELL") filed a complaint requesting that the ITC commence an investigation pursuant to section 337.

On February 8, 2021, the ITC issued the public version of its opinion in Certain Motorized Self-Balancing Vehicles (Inv. No. 337-TA-1000).

In Allergan USA, Inc v Sun Pharmaceutical Indus. Ltd, Appeal No. 2024-1061, August 13, 2024, the Federal Circuit reversed the district court's holding that Allergan patent, U.S.P. 7,741,356 (‘356) was invalid...

On February 16, 2021, the ITC issued a Notice of Investigation in Certain Cellular Communications Infrastructure Systems, Components Thereof, and Products Containing the Same (Inv. 337-TA-1248).

The USPTO's new Director Review Process is reshaping patent proceedings at the Patent Trial and Appeal Board, with recent decisions showing how patent owners can successfully challenge unpatentability findings for dependent claims.

Further to our communications of December 10, 2021 and December 15, 2021, regarding the U.S. Patent and Trademark Office (USPTO)'s transition to electronic issuance of U.S. patents and U.S. trademark registration certificates, ...

On March 13, 2026, the United States Patent and Trademark Office (USPTO) issued supplemental guidance that provides design patent applicants with greater flexibility when claiming...

On July 20, 2021, and in response to the Office's request for feedback on the interim Director review process, the USPTO has updated and revised its Arthrex Q&As to clarify certain aspects of the interim procedure.

On February 13, the U.S. Court of Appeals for the Federal Circuit (CAFC) reversed the decision of the International Trade Commission (ITC) in US Synthetic Corp. v. International Trade Commission...

35 U.S.C. § 315(e)(1) and (2) are the statutory provisions regarding petitioner estoppel in IPRs.

On July 16, 2019, the Patent Office published its 2019 Trial Practice Guide Update, a copy of which can be found here.

In the April 29, 2023 article, the Yomiuri Shimbun reported that a group of creative artists met with government official to discuss legal protections from generative artificial...

The meeting addressed the increasing risk of copyright violations, as AI technology allows the creation of text or images closely resembling original works.

On Tuesday, the FTC announced that it is cracking down on companies it asserts is improperly or inaccurately placing drugs on the list of FDA-approved products...

Post grant reviews (PGRs) have proven to be more popular in the biotechnology space (TC 1600) than any other art unit, with 42—or 28.1%—of the PGRs filed to date classified as TC 1600 patents.

On September 24, 2018, the Solicitor General filed a motion to participate in oral argument as amicus curiae in Helsinn Healthcare v. Teva Pharmaceuticals.

Orphan drug exclusivity was created in 1983 to encourage pharmaceutical companies to develop drugs for diseases which affect less than 200,000 persons in the U.S. Jazz Pharmaceuticals...

Teva Pharmaceutical USA, Inc. filed a Complaint and Motion for Preliminary Injunction in the U.S. District Court for the District of Columbia, ...

The USPTO today published its guidance to the examiners on the impact of the Amgen v. Sanofi,143 S. Ct. 1243 (2023), on USPTO practice.

The USPTO has recently reported fee increases to take effect on October 2, 2020 relating to the filing and prosecution of patent applications and the maintenance of patents.